Patents by Inventor Pierre Coulie

Pierre Coulie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Endogenous retrovirus tumor associated nucleic acids and antigens
    Patent number: 6770456
    Abstract: The invention describes HERV-AVL3-B tumor associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a HERV-AVL3-B gene product.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: August 3, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre Coulie, Thierry Boon-Falleur
  • Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
    Patent number: 6682731
    Abstract: Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: January 27, 2004
    Assignees: Ludwig Institute for Cancer Research, The Chancellor Masters & Scholars of the University of Oxford, University of Leiden
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre Van Der Bruggen, Pierre Coulie, Thomas Gajewski, Cornelis J. M. Melief, Marjan J. W. Visseren, Martin W. Kast
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-CW 1601/MAGE-1 DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6680056
    Abstract: Peptides which satisfy the formula of SEQ ID NO: 10 bind to HLA-Cw*1601 molecules, and stimulate proliferation of cytolytic T cells. Examples of such peptides are those set forth in SEQ ID NOS: 4 and 5.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: January 20, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Jean-Pierre Szikora, Pierre Coulie, Claude Wildmann, Pascale Boël, Thierry Boon-Falleur
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6669946
    Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
  • Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens
    Patent number: 6638512
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: October 28, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
    Publication number: 20030158388
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.
    Type: Application
    Filed: September 30, 2002
    Publication date: August 21, 2003
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Micaela Carrel, Alexandra Carrel, Julien Carrel, Daryl Reed
  • Method for determining BAGE expression
    Publication number: 20030138854
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Application
    Filed: February 20, 2002
    Publication date: July 24, 2003
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Immunogenic compositions of tumor rejection antigen precursor MAGE-10 and an adjuvant
    Patent number: 6497879
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: December 24, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
  • Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof
    Patent number: 6465184
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: October 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
    Publication number: 20020128200
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Application
    Filed: December 11, 2001
    Publication date: September 12, 2002
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
    Patent number: 6387698
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: May 14, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
  • Isolated nucleic acid molecules which encode tumor rejection antigens found in dage
    Patent number: 6339149
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: January 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre Coulie, Hideyuki Ikeda, Thierry Boon-Falleur
  • Methods for treating subject with DAGE derived peptides
    Patent number: 6297050
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: October 2, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre Coulie, Hideyuki Ikeda, Thierry Boon-Falleur
  • Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 6284476
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
  • Isolated protein processed to peptides which form complexes with HLA molecules
    Patent number: 6245333
    Abstract: A nucleic acid molecule which codes for a tumor rejection antigen precursor which is in turn processed to antigens presented by an HLA molecule is described. The HLA molecule may be HLA-A2, HLA-A28, HLA-B13, HLA-B44, or HLA-Cw6. The antigens are also described. These materials are useful in diagnostic and therapeutic methodologies. The tumor rejection antigen precursor is not tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: June 12, 2001
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pierre Coulie, Thierry Boon-Falleur
  • Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
    Patent number: 6201111
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 13, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wölfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
    Patent number: 6174692
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: January 16, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
  • Isolated peptide defined by SEQ ID NO: 17 and uses thereof
    Patent number: 6171806
    Abstract: Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: January 9, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Herman, Pierre Coulie, Pierre van der Bruggen, Thierry Boon-Falleur
  • Isolated tumor rejection antigen precursor MAGE-10 and compositions containing it
    Patent number: 6153728
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: November 28, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
  • Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules
    Patent number: 6110694
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: August 29, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld